<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA Intern Med</journal-id><journal-id journal-id-type="iso-abbrev">JAMA Intern Med</journal-id><journal-id journal-id-type="pmc-domain-id">3211</journal-id><journal-id journal-id-type="pmc-domain">jamasd</journal-id><journal-title-group><journal-title>JAMA Internal Medicine</journal-title></journal-title-group><issn pub-type="ppub">2168-6106</issn><issn pub-type="epub">2168-6114</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>JAMA Network</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11811872</article-id><article-id pub-id-type="pmcid-ver">PMC11811872.1</article-id><article-id pub-id-type="pmcaid">11811872</article-id><article-id pub-id-type="pmcaiid">11811872</article-id><article-id pub-id-type="pmid">39928325</article-id><article-id pub-id-type="doi">10.1001/jamainternmed.2024.7810</article-id><article-id pub-id-type="publisher-id">ioi240094</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="domain" specific-use="print"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group><subj-group subj-group-type="online-first"><subject>Online First</subject></subj-group></article-categories><title-group><article-title>Medicare Opioid Policy and Opioid Use in Beneficiaries With Disabilities</article-title><alt-title alt-title-type="headline">Medicare Opioid Policy and Opioid Use in Beneficiaries With Disabilities</alt-title><alt-title alt-title-type="running-head">Medicare Opioid Policy and Opioid Use in Beneficiaries With Disabilities</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Wen</surname><given-names initials="H">Hefei</given-names></name><degrees>PhD</degrees><xref rid="ioi240094aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ioi240094aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Halbisen</surname><given-names initials="A">Alyssa</given-names></name><degrees>MPH</degrees><xref rid="ioi240094aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Thomas</surname><given-names initials="AM">Ann M.</given-names></name><degrees>PhD</degrees><xref rid="ioi240094aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lakoma</surname><given-names initials="M">Matthew</given-names></name><degrees>MPH</degrees><xref rid="ioi240094aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Argetsinger</surname><given-names initials="S">Stephanie</given-names></name><degrees>MPH</degrees><xref rid="ioi240094aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="F">Fang</given-names></name><degrees>PhD</degrees><xref rid="ioi240094aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ioi240094aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Burns</surname><given-names initials="ME">Marguerite E.</given-names></name><degrees>PhD</degrees><xref rid="ioi240094aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Johnston</surname><given-names initials="KJ">Kenton J.</given-names></name><degrees>PhD</degrees><degrees>MPH</degrees><xref rid="ioi240094aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shuey</surname><given-names initials="B">Bryant</given-names></name><degrees>MD</degrees><degrees>MPH</degrees><xref rid="ioi240094aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wharam</surname><given-names initials="JF">James Franklin</given-names></name><degrees>MD</degrees><degrees>MPH</degrees><xref rid="ioi240094aff6" ref-type="aff">
<sup>6</sup>
</xref><xref rid="ioi240094aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib></contrib-group><aff id="ioi240094aff1"><label>1</label>Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts</aff><aff id="ioi240094aff2"><label>2</label>Harvard Medical School, Boston, Massachusetts</aff><aff id="ioi240094aff3"><label>3</label>Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin, Madison</aff><aff id="ioi240094aff4"><label>4</label>Department of Medicine, Washington University School of Medicine, St Louis, Missouri</aff><aff id="ioi240094aff5"><label>5</label>Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania</aff><aff id="ioi240094aff6"><label>6</label>Department of Medicine, Duke University School of Medicine, Durham, North Carolina</aff><aff id="ioi240094aff7"><label>7</label>Duke-Margolis Institute for Health Policy, Durham, North Carolina</aff><author-notes><title>Article Information</title><p><bold>Accepted for Publication:</bold> December 9, 2024.</p><p content-type="published-online"><bold>Published Online:</bold> February 10, 2025. doi:<uri content-type="doi">10.1001/jamainternmed.2024.7810</uri></p><corresp id="ioi240094cor1"><bold>Corresponding Author:</bold> Hefei Wen, PhD, Department of Population Medicine, Harvard Medical School &amp; Harvard Pilgrim Health Care Institute, 401 Park Dr, Ste 401 E, Boston, MA 02215 (<email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="hefei_wen@hphci.harvard.edu">hefei_wen@hphci.harvard.edu</email>).</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Dr Wen had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p><p><italic toggle="yes">Concept and design</italic>: Wen, Wharam.</p><p><italic toggle="yes">Acquisition, analysis, or interpretation of data</italic>: All authors.</p><p><italic toggle="yes">Drafting of the manuscript</italic>: Wen, Shuey.</p><p><italic toggle="yes">Critical review of the manuscript for important intellectual content</italic>: All authors.</p><p><italic toggle="yes">Statistical analysis</italic>: Wen, Thomas, Lakoma, Zhang, Shuey, Wharam.</p><p><italic toggle="yes">Obtained funding</italic>: Wen.</p><p><italic toggle="yes">Administrative, technical, or material support</italic>: Halbisen, Thomas, Argetsinger, Shuey.</p><p><italic toggle="yes">Supervision:</italic> Wen, Johnston, Wharam.</p><p><italic toggle="yes">Other:</italic> Burns.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Argetsinger reported grants from Harvard Pilgrim Health Care Institute during the conduct of the study. Dr Zhang reported grants from Pfizer and GlaxoSmithKline for postmarket safety studies outside the submitted work. Dr Johnston reported grants from the Laura and John Arnold Foundation, speaking honorarium from the St Louis Area Business Health Coalition, and consulting fees from Brown University outside the submitted work. Dr Shuey reported grants from US National Institute on Drug Abuse (K12DA050607) during the conduct of the study. No other disclosures were reported.</p><p content-type="funding-statement"><bold>Funding/Support:</bold> The US National Institute on Drug Abuse supported this work (grant R01DA055131).</p><p><bold>Role of the Funder/Sponsor:</bold> The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p><p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-IOI240094-1-s" ref-type="supplementary-material">Supplement 2</xref>.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2025-02-10T10:00"><day>10</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>4</month><year>2025</year></pub-date><volume>185</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">481870</issue-id><fpage>422</fpage><lpage>430</lpage><history><date date-type="received"><day>18</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>9</day><month>12</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>10</day><month>02</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-04-09 00:25:24.177"><day>09</day><month>04</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright 2025 American Medical Association. All rights reserved, including those for text and data mining, AI training, and similar technologies.</copyright-statement></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jamainternmed-e247810.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf-version" xlink:href="jamainternmed-e247810.pdf">jamainternmed-e247810.pdf</self-uri><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="silverchair" xlink:href="https://jamanetwork.com/journals/archinte/fullarticle/10.1001/jamainternmed.2024.7810"/><abstract abstract-type="key-points"><title>Key Points</title><sec id="ab-ioi240094-1"><title>Question</title><p>Was the 2019 Medicare opioid policy effective in limiting initial opioid prescription duration (7-day safety edit) and dosage (90&#8722;morphine milligram equivalence [MME] safety edit) in beneficiaries with disabilities?</p></sec><sec id="ab-ioi240094-2"><title>Findings</title><p>This interrupted time-series study found that in a cohort that was new to opioid use (476&#8201;859 patients), the 7-day safety edit was associated with a sustained reduction in the days&#8217; supply of an initial opioid fill; however, reductions in 30-day total MME and likelihood of developing long-term opioid use diminished over time. In addition, in a cohort with long-term opioid use (3&#8201;295&#8201;299 patients), the 90-MME safety edit was associated with a reduction in concurrent multiple prescriber high-dosage episodes, but this improvement was reversed when COVID-19 policies rolled back the patient-prescriber consultation requirement.</p></sec><sec id="ab-ioi240094-3"><title>Meaning</title><p>These findings indicate that the 2019 Medicare opioid safety policy was associated with reductions in initial opioid prescription duration and concurrent multiple-prescriber high-dosage episodes.</p></sec></abstract><abstract><sec id="ab-ioi240094-4"><title>Importance</title><p>Medicare beneficiaries with disabilities have excess opioid-related morbidity and mortality. A 2019 Medicare opioid safety policy was designed to address high-risk opioid prescribing and related harms by limiting the initial duration to 7 days and restricting high daily dosage across multiple prescribers.</p></sec><sec id="ab-ioi240094-5"><title>Objective</title><p>To evaluate the association of the 2019 Medicare opioid 7-day and 90&#8722;morphine milligram equivalence (MME) safety edits with opioid use among beneficiaries with disabilities.</p></sec><sec id="ab-ioi240094-6"><title>Design, Setting, and Participants</title><p>This interrupted time-series study used claims data from Optum&#8217;s deidentified Clinformatics Data Mart database to assess changes in opioid prescriptions and use among Medicare Advantage beneficiaries (younger than 65 years) with disability entitlements from June 2016 to September 2021. The analysis compared opioid use outcomes before and after the safety policy was implemented in 2019 (including the COVID-19 pandemic) in 2 cohorts of patients (new to opioids vs long-term opioid use). Data analyses were performed from September 2023 to October 2024.</p></sec><sec id="ab-ioi240094-7"><title>Exposures</title><p>Implementation of the Medicare opioid 7-day and 90-MME safety edits in January 2019.</p></sec><sec id="ab-ioi240094-8"><title>Main Outcomes and Measures</title><p>Likelihood of an initial opioid prescription more than 7 days&#8217; supply and 30-day total MME; likelihood of development of long-term opioid use in a new-to-opioid cohort; the number of concurrent multiple-prescriber high-dosage episodes in a long-term opioid cohort.</p></sec><sec id="ab-ioi240094-9"><title>Results</title><p>The new-to-opioids cohort included 476&#8201;859 person&#8722;index months (mean [SD] age, 55.7 [7.8] years; 281&#8201;536 [59.0%] women). The long-term opioid cohort included 3&#8201;295&#8201;299 person&#8722;index months (mean [SD] age, 56.3 years [6.6]; 1 887 547 [57.3%] men and 1&#8201;407&#8201;752 [42.7%] women). The 7-day safety edit was associated with immediate and sustained reductions in the likelihood of an initial opioid prescription filled for more than 7 days&#8217; supply (start of the post-policy period: 46.7 % reduction; 99.5% CI, &#8722;48.3% to &#8722;45.2%; end of study period: 43.8% reduction; 99.5% CI, &#8722;45.7% to &#8722;41.9%). In contrast, moderate immediate reductions in the likelihood of development into long-term opioid use (13.8% reduction; 99.5% CI, &#8722;20.5% to &#8722;7.2%) diminished by the end of the study period (4.0% reduction; 99.5% CI, &#8722;10.4% to 2.4%). The 90-MME safety edit was associated with an immediate 36.1% reduction (99.5% CI, &#8722;42.8% to &#8722;29.4%) in the number of concurrent multiple-prescriber high-dosage episodes, which was reversed when the COVID-19 flexibility rolled back the 90-MME edit.</p></sec><sec id="ab-ioi240094-10"><title>Conclusions and Relevance</title><p>The findings of this interrupted time-series study of Medicare Advantage beneficiaries younger than 65 years with disabilities show that the 2019 Medicare opioid safety policy was associated with shorter initial duration of opioid prescriptions and fewer concurrent multiple prescriber high-dosage prescriptions of opioids. Given that downstream reductions appeared to be transient, further interventions are needed to address the clinical and social risk factors for opioid misuse among beneficiaries with disabilities.</p></sec></abstract><abstract abstract-type="teaser" specific-use="electronic"><p>This interrupted time-series cohort study examines the association of the 2019 Medicare opioid safety edits with changes in opioid use among beneficiaries with disabilities.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-exception-type</meta-name><meta-value>EMBARGO</meta-value></custom-meta><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>4</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>no</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>